【国创上头条】既有CD47,又有PD-L1,盘点最新5款获授权引进中国的创新药( 三 )
[3]信达生物与Alector达成合作 在中国开发和商业化抗SIRP-alpha抗体. Retrieved March 26 , 2020, from https://www.prnasia.com/story/275928-1.shtml
[4]Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset. Retrieved March 24 , 2020, from https://www.businesswire.com/news/home/20200324005279/en/Laekna-Acquires-Exclusive-Global-Rights-Clinical-Stage-Cancer?from=singlemessage&isappinstalled=0
[5]Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China. Retrieved Mar 19 2020 from https://www.tarvedatx.com/3-19-20-tarveda-therapeutics-and-sciclone-pharmaceuticals-international-establish-licensing-agreement-for-pen-866-in-greater-china
推荐阅读
- 「趣头条」豪华运动轿车的代表,坚持进口不国产,Ghibli起售价88.08万元
- 趣头条@“养活”1辆布加迪,到底需要多少钱?网友:中10几次500万都不够
- [趣头条]一睹庐山真面目之传说中的县衙
- #趣头条#秋日午后,宁静而温暖!静态赏析秋与雷凌的温暖午后
- 趣头条:【拍摄帖】#爱风神,享生活#一路有你风神奕炫伴我前行用车感受
- 趣头条@【桑塔纳的平淡生活】爬山,感受大自然气息
- 『趣头条』夕阳下的你是那么好看——我与途昂的日常
- 「趣头条」我的吉利帝豪,相伴许久的感受~
- 趣头条@门前大桥上,来一辆奕歌
- 趣头条■全新大众途昂X上市,售价28.99-43.99万,配置全面优化升级
